BNR

Burning Rock Biotech
BNR

17.09 USD
+0.09
0.53%
At close Updated May 1, 4:00 PM EDT
1 day
0.53%
5 days
-18.42%
1 month
4.85%
3 months
-56.77%
6 months
39.4%
Year to date
-13.16%
1 year
495.47%
5 years
-94.03%
10 years
-93.06%
 

About: Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Employees: 667

Healthcare Diagnostics & Research
0
Funds holding %
of 8,127 funds
Explore Fund Trends
–
Analysts bullish %
See Analyst Outlook
–
Positive news %
Check Journalist POV
Price charts implemented using Lightweight Charts™